| Role of macrophage targeting in the antitumor activity of trabectedin G Germano, R Frapolli, C Belgiovine, A Anselmo, S Pesce, M Liguori, ... Cancer cell 23 (2), 249-262, 2013 | 931 | 2013 |
| Role of α1 Acid Glycoprotein in the In Vivo Resistance of Human BCR-ABL+ Leukemic Cells to the Abl Inhibitor STI571 C Gambacorti-Passerini, R Barni, P le Coutre, M Zucchetti, G Cabrita, ... Journal of the National Cancer Institute 92 (20), 1641-1650, 2000 | 491 | 2000 |
| α1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients C Gambacorti-Passerini, M Zucchetti, D Russo, R Frapolli, M Verga, ... Clinical cancer research 9 (2), 625-632, 2003 | 280 | 2003 |
| Distribution of paclitaxel within the nervous system of the rat after repeated intravenous administration G Cavaletti, E Cavalletti, N Oggioni, C Sottani, C Minoia, M D'incalci, ... Journal of the Peripheral Nervous System 6 (1), 61-61, 2001 | 226 | 2001 |
| High-dose vitamin C enhances cancer immunotherapy A Magrì, G Germano, A Lorenzato, S Lamba, R Chilà, M Montone, ... Science translational medicine 12 (532), eaay8707, 2020 | 203 | 2020 |
| Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors JC Soria, F DeBraud, R Bahleda, B Adamo, F Andre, R Dientsmann, ... Annals of oncology 25 (11), 2244-2251, 2014 | 195 | 2014 |
| Do anticancer agents reach the tumor target in the human brain? MG Donelli, M Zucchetti, M D'Incalci Cancer chemotherapy and pharmacology 30 (4), 251-260, 1992 | 187 | 1992 |
| Blockade of the IL-1R1/TLR4 pathway mediates disease-modification therapeutic effects in a model of acquired epilepsy V Iori, AM Iyer, T Ravizza, L Beltrame, L Paracchini, S Marchini, M Cerovic, ... Neurobiology of disease 99, 12-23, 2017 | 184 | 2017 |
| A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia C Rizzari, M Citterio, M Zucchetti, V Conter, R Chiesa, A Colombini, ... haematologica 91 (1), 24-31, 2006 | 148 | 2006 |
| Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function M D'Incalci, C Rossi, M Zucchetti, R Urso, F Cavalli, C Mangioni, ... Cancer research 46 (5), 2566-2571, 1986 | 144 | 1986 |
| Pharmacokinetics of anticancer agents in patients with impaired liver function MG Donelli, M Zucchetti, E Munzone, M D’Incalci, A Crosignani European journal of cancer 34 (1), 33-46, 1998 | 140 | 1998 |
| L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving im or iv Erwinia C. or E. coli L-asparaginase as first exposure C Rizzari, M Zucchetti, V Conter, L Diomede, A Bruno, L Gavazzi, ... Annals of oncology 11 (2), 189-193, 2000 | 130 | 2000 |
| Chemical characterization of Iraqi propolis samples and assessing their antioxidant potentials GM Sulaiman, KW Al Sammarrae, AH Ad’hiah, M Zucchetti, R Frapolli, ... Food and Chemical Toxicology 49 (9), 2415-2421, 2011 | 126 | 2011 |
| IDN5109, a taxane with oral bioavailability and potent antitumor activity MI Nicoletti, T Colombo, C Rossi, C Monardo, S Stura, M Zucchetti, A Riva, ... Cancer Research 60 (4), 842-846, 2000 | 111 | 2000 |
| Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial … L Ansaloni, F Coccolini, L Morosi, A Ballerini, M Ceresoli, G Grosso, ... British journal of cancer 112 (2), 306-312, 2015 | 110 | 2015 |
| Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex C Sessa, G Capri, L Gianni, F Peccatori, G Grasselli, J Bauer, M Zucchetti, ... Annals of Oncology 11 (8), 977-984, 2000 | 108 | 2000 |
| Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents M Cesca, F Bizzaro, M Zucchetti, R Giavazzi Frontiers in oncology 3, 259, 2013 | 101 | 2013 |
| Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies D Meco, T Colombo, P Ubezio, M Zucchetti, M Zaffaroni, A Riccardi, ... Cancer chemotherapy and pharmacology 52, 131-138, 2003 | 96 | 2003 |
| A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma E Gallerani, M Zucchetti, D Brunelli, E Marangon, C Noberasco, D Hess, ... European journal of cancer 49 (2), 290-296, 2013 | 95 | 2013 |
| Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat S Donald, RD Verschoyle, P Greaves, TW Gant, T Colombo, M Zaffaroni, ... Cancer Research 63 (18), 5902-5908, 2003 | 88 | 2003 |
Roberta FrapolliIstituto di Ricerche Farmacologiche Mario Negri在 marionegri.it 的电子邮件经过验证
